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Abstract
Background: The cancer stem cell theory hypothesizes that cancers are perpetuated by cancer stem cells (CSC) or tumor
initiating cells (TIC) possessing self-renewal and other stem cell-like properties while differentiated non-stem/initiating cells
have a finite life span. To investigate whether the hypothesis is applicable to lung cancer, identification of lung CSC and
demonstration of these capacities is essential.
Methodology/Principal Finding: The expression profiles of five stem cell markers (CD34, CD44, CD133, BMI1 and OCT4)
were screened by flow cytometry in 10 lung cancer cell lines. CD44 was further investigated by testing for in vitro and in vivo
tumorigenecity. Formation of spheroid bodies and in vivo tumor initiation ability were demonstrated in CD44+ cells of 4 cell
lines. Serial in vivo tumor transplantability in nude mice was demonstrated using H1299 cell line. The primary xenografts
initiated from CD44+ cells consisted of mixed CD44+ and CD442 cells in similar ratio as the parental H1299 cell line,
supporting in vivo differentiation. Semi-quantitative Real-Time PCR (RT-PCR) showed that both freshly sorted CD44+ and
CD44+ cells derived from CD44+-initiated tumors expressed the pluripotency genes OCT4/POU5F1, NANOG, SOX2. These
stemness markers were not expressed by CD442 cells. Furthermore, freshly sorted CD44+ cells were more resistant to
cisplatin treatment with lower apoptosis levels than CD442 cells. Immunohistochemical analysis of 141 resected non-small
cell lung cancers showed tumor cell expression of CD44 in 50.4% of tumors while no CD34, and CD133 expression was
observed in tumor cells. CD44 expression was associated with squamous cell carcinoma but unexpectedly, a longer survival
was observed in CD44-expressing adenocarcinomas.
Conclusion/Significance: Overall, our results demonstrated that stem cell-like properties are enriched in CD44-expressing
subpopulations of some lung cancer cell lines. Further investigation is required to clarify the role of CD44 in tumor cell
renewal and cancer propagation in the in vivo environment.
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Introduction
Lung cancer is the leading cause of cancer deaths worldwide.
The overall prognosis is poor with low 5 year survival due to late
presentation, disease relapse and lack of curative systemic therapy.
Recently, the cancer stem cells (CSC) theory proposes that cancers
are maintained by subpopulations of tumor cells that possess stem
or progenitor cell characteristics. These cells can initiate tumor
formation, differentiate along multi-potent pathways and are
relatively resistant to conventional chemotherapy [1]. CSC have
been demonstrated in haematological and some solid tumors such
as breast, brain, colon, lung and liver cancers [2,3,4,5,6]. Various
stem cell markers of normal tissues have been used for CSC
identification and isolation. For example, CD133 is the most
frequently demonstrated marker in cancers of the liver, brain,
colon and lung, etc [3,4,5,6]. The CD44+/CD242/low profile
characterizes CSC in breast and prostate cancers [7,8]. Expression
of the key ‘stemness’ genes of embryonic (ES) and induced-
pluripotent stem (iPS) cells OCT4 and BMI1 [9,10] have been
found in CSC from different cancers [11,12].
The marker profile of lung CSC remains to be explored. Recent
studies using NSCLC cell lines and fresh lung tumor tissues suggest
CD133 as the lung CSC marker [3,11,13,14,15,16]. Biochemical
studies showed that CD133 plays a functional role in cell cycle
regulation and proliferation but not tumor initiation [17]. Studies
in colon cancer showed that CD133+ cells have a higher DNA
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content [18] and become CD1332 during metastasis, but both
CD133+ and CD1332 cells initiate tumor in SCID mice [19].
CD1332 populations from colon cancer and melanoma were also
found to be tumorigenic in SCID/nude mice [19,20]. Markers
such as ESA, CXCR4, ALDH and ABCG2 have been used with
CD133 for isolating CSC from lung cancers [13,21,22]. CD34 and
Sca-1 are useful for identifying murine lung stem cells but Sca-1 is
not expressed in human tissues [23]. To explore further lung CSC
markers, we have screened the expression profile of CD34, CD44,
CD133, BMI1 and OCT4 in 10 lung cancer cell lines by flow
cytometry. We demonstrated that CD44+ but not CD442 cells
from selective cancer cell lines could be expanded and serially
propagated in vitro and in vivo. We propose that CD44-expressing
cells are enriched for stem cell properties. Our study does not show
that all CD44+ cells are bona fide CSC, however, we propose that
CD44 could be a marker of tumor initiation ability in some lung
cancer cells. The expression pattern of CD44 was also character-
ized in clinical lung cancers.
Results
Stem cell marker expression profile of NSCLC cell lines
We analyzed the expression profile of putative surface (CD34,
CD44, CD133) and nuclear markers (BMI1, OCT4) of stem cells
in 10 lung cancer cell lines using flow cytometry (Table 1). Of the
surface markers, CD34, CD44 and CD133 were expressed at
various frequencies. CD44 was the major marker expressed by
H1299 and H23. A549, H441 and H1648 showed no expression
of the surface markers studied. CD133 was expressed in HCC1833
only. No correlation in expression frequency was observed
between any 2 markers. Both the nuclear markers, BMI1 and
OCT4, were expressed in the majority of cancer cells in all cell
lines studied. Representative diagrams of flow cytometry analysis
for CD44 and CD133 expression were shown in Fig 1.
Immunoblotting and immunohistochemistry (IHC) analyses were
also performed on cell lines that contained CD44+ and CD133+
populations (Fig 2A). Immunoblot showed CD44 protein expres-
sion in H1650, HKULC2, H1299, HKULC4, HCC827 and H23.
CD133 protein was only expressed in HCC1833 and PLC8024
which was used as a positive control cell line for CD133 [4]. IHC
also showed CD133 expression in HCC1833 but not H1299, and
vice versa for CD44 expression. Thus, results of both analyses
were in line with flow cytometry data.
Spheroid formation ability of NSCLC cell lines
We next assessed spheroid body (SB) formation ability of FASC-
fractionated cells according to CD44 and CD133 expression in 7
cell lines. 500 unsorted, marker+ and marker2 cells, respectively,
were cultured in non-adhesive and serum-free conditions with
EGF, bFGF and insulin supplements for 21 days. The percentage
of SB formation of each cell line was counted by random field
selection at day 21 and results were plotted as histograms
(Supplementary Figure S1). Unsorted cells from all 7 cell lines
were able to form SB. SB were also formed from CD44+
subpopulations of 6 cell lines in which CD44 was expressed, but
not from the CD442 subpopulations. In addition, HKULC2,
H1299 and H1650 which contained lower initial proportions of
CD44+ cells gave rise to significantly more SB compared to
unsorted cells (*p,0.05, **p,0.01). For HCC1833, CD133+ but
not CD1332 cells formed SB. The increase in SB numbers from
CD133+ compared to unsorted cells was not statistically
significant. After 21 days, all SB from H1299 CD44+ cells were
dissociated into single cells and re-suspended in culture media. Up
to three serial passages were established, indicating in vitro self-
renewal of the CD44+ cells. Flow cytometry analysis of the first
generation SB cells from H1299 showed 81.58% of CD44+ cells,
which closely resembled the 81.3% of the parental cells,
demonstrating that in vitro tumorigenecity from CD44+ cells
resulted in a progeny with the same profile of CD44 expression
(Fig. 2B). Clonogenicity assay in soft agar also showed that freshly
isolated H1299 CD44+ cells formed significantly more colonies
than CD442 cells in 3 weeks (**p,0.01), supporting enhanced
self-renewal capacity of CD44-selected cells (Fig. 2C).
In vivo tumor-initiating properties of CD44+ cells and
sequential increase of transplantation efficiency in nude
mice
The ability of the marker-selected cells to initiate in vivo tumor
was investigated by subcutaneous transplantation into nude mice.
For H1299, HKULC4, H1650 and HCC827, as few as 10,000
CD44+ cells were able to initiate tumors in 30–68 days (Table 2),
but no tumor was formed from the same number of unsorted or
CD442 cells after 90 days. For unsorted cells of H1299, tumor
initiation could be achieved by 200,000 cells (3/4 mice), while with
CD44+ cells, tumors were initiated by 10,000 (1/4 mice), 50,000
(3/4 mice) and 100,000 cells (4/4 mice). For CD442 cells, no
tumor was formed even using 200,000 cells (0/4 mice) (Fig. 3A-
representative tumors, Table 2). We have dissected the mice and
examined all the organs and found no metastatic tumor formation
from the sorted or unsorted cells under the observed period. For
HKULC2 and H23, although SB formation was observed, no
xenograft tumor was formed using 200,000 unsorted, CD44+ or
CD442 cells. Likewise, 200,000 unsorted, CD133+ or CD1332
HCC1833 cells did not form tumors.
The next experiments tested whether the tumor initiation
capacity could be propagated in vivo. Since H1299 CD44+ showed
the shortest latency of tumor formation (Table 2), we dissociated
H1299 primary tumor to demonstrate in vivo serial tranplantability.
Only viable tumor cells from disaggregated H1299 xenografts
were selected for serial tumor transplantation into secondary, and
subsequently, tertiary recipient mice. Tumors were formed from
CD44+ but not CD442 cells (Table 3). Notably, although the
proportions of live CD44+ cells (47.73% for primary, 0.91% for
secondary) (Fig 3B) were reduced on serial transplantation, the
Table 1. Expression of Putative Cancer Stem Cell Markers in
NSCLC Cell Lines.
Cell lines CD34 CD44 CD133 BMI1 OCT4
1 H1650 2.9 61.7 0.0 99.6 70.7
2 HKULC2* 10.3 68.6 0.0 92.3 98.3
3 H1299 0.0 81.3 0.0 89.1 73.8
4 HKULC4* 7.8 82.4 0.0 94.3 87.6
5 HCC827 9.2 82.5 0.0 98.1 88.3
6 H23 0.1 95.9 0.0 99.9 91.0
7 HCC1833 2.3 0.0 80.0 97.4 99.1
8 A549 0.0 0.0 0.0 97.5 97.0
9 H441 0.0 0.0 0.0 99.9 99.9
10 H1648 0.0 0.0 0.0 99.1 99.7
*Cell lines raised from local patients (46).
Results represented average of three individual flow cytometry experiments.
doi:10.1371/journal.pone.0014062.t001
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Figure 1. Surface marker expression profile. Representative diagrams of flow cytometry analysis of CD44 (FITC) and CD133 (PE) expression in
lung cancer cell lines HKULC2, HCC827, HKULC4, H23, HCC1833, H1299 and H1650. Dead cells, cell debris and doublets were gated out.
Compensation for background fluorescence was performed by measuring target signals of single color controls and negative controls. Data were
presented in 2D diagrams plotting either PE or FITC signals against an irrelevant channel ECDH (also known as PE-Texas Red). The average
percentages from 3 individual analyses were presented in Table 1.
doi:10.1371/journal.pone.0014062.g001
CD44-Cancer Stem Cell Marker
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Figure 2. In vitro tumorigenecity of NSCLC cells. A. Representative immunoblot of H1650, HKULC2, H1299, HKULC4, HCC827, H23, HCC1833 and
PLC8024 total protein lysate using antibodies against CD44 and CD133. Actin was used as a loading control. The blot was representative of three
individual experiments. B. Overall view to show density of SB formation from CD44+ and CD442 H1299 cells after culturing in RPMI medium with EGF,
FGF and insulin supplement for 21 days (upper panel), and morphology of SB at weekly intervals (middle panel). Cells of the first generation SB were
disaggregated and analyzed by flow cytometry (lower panel). The CD44+ to CD442 (81.58% to 9.68%) ratio was similar to that of the parental H1299
cells (81.3% to 18.7%, Table 1). SSC, Side Scatter Channel. C. Representative fields of colony formation of unsorted, CD44+ and CD442 H1299 cells in
soft-agar after culturing for 21 days. Insets show magnified views of representative colonies from the respective cells taken under the same
magnification. CD442 subgroup showed significantly fewer colonies compared to both CD44+ and unsorted subgroups. (**, p,0.01). Histograms
represented average of 3 independent observations from separate experiments.
doi:10.1371/journal.pone.0014062.g002
CD44-Cancer Stem Cell Marker
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e14062
efficiency of tumor initiation increased in successive generations of
tumor. The latency of tumor formation from 5,000 CD44+ cells
was progressively shortened from 30 days of the first generation, to
21 days of the second and 14 days of the tertiary generation,
respectively. The number of cells required to initiate tertiary
tumors also decreased to 1,000 CD44+ cells.
To analyze the differentiation capacity of CD44+ cells, the
harvested tumors were disaggregated and subjected to flow
cytometry analysis. The CD44+:CD442 ratio of the primary
tumor was 80.72:17.0, and of the secondary tumor was 85.4:12.53.
These were in the same range as the parental cells (81.3: 18.7),
demonstrating similar CD44 expression hierarchy of sequential
generations of xenografts (Fig. 3B). Further analysis of the primary
tumor by RT-PCR revealed the expression of the pluripotency
markers POU5F1, NANOG and SOX2 in CD44+ but not CD442
subpopulations (Fig. 3C).
Fig. 3D shows representative IHC staining for CD44 and tumor
growth curves of the primary and serially transplanted xenografts.
Table 2. In Vivo Tumorigenecity of Marker+/2 NSCLC cells.
Cell type Cell number injected Tumor incidence Latency (days)
H1299 unsorted 10,000 0/4 N/A
50,000 0/4 N/A
200,000 3/4 30
H1299 CD442 10,000 0/4 N/A
50,000 0/4 N/A
200,000 0/4 N/A
H1299 CD44+ 10,000 1/4 30
50,000 3/4 30
100,000 4/4 30
HKULC4 unsorted 10,000 0/4 N/A
200,000 4/4 35
HKULC4 CD442 10,000 0/4 N/A
HKULC4 CD44+ 10,000 1/4 35
H1650 unsorted 10,000 0/4 N/A
200,000 4/4 60
H1650 CD442 10,000 0/4 N/A
H1650 CD44+ 10,000 2/4 60
HCC827 unsorted 10,000 0/4 N/A
200,000 4/4 68
HCC827 CD442 10,000 0/4 N/A
HCC827 CD44+ 10,000 3/4 68
HKULC2 unsorted 10,000 0/4 N/A
200,000 0/4 N/A
HKULC2 CD442 10,000 0/4 N/A
200,000 0/4 N/A
HKULC2 CD44+ 10,000 0/4 N/A
200,000 0/4 N/A
H23 unsorted 10,000 0/4 N/A
200,000 0/4 N/A
H23 CD442 10,000 0/4 N/A
200,000 0/4 N/A
H23 CD44+ 10,000 0/4 N/A
200,000 0/4 N/A
HCC1833 unsorted 10,000 0/4 N/A
200,000 0/4 N/A
HCC1833 CD1332 10,000 0/4 N/A
200,000 0/4 N/A
HCC1833 CD133+ 10,000 0/4 N/A
200,000 0/4 N/A
N/A: results not available.
doi:10.1371/journal.pone.0014062.t002
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As shown by the tumor growth curve, the primary and serially
transplanted tumors initiated from 50,000 CD44+ cells grew faster
than 200,000 unsorted cells.
CD44+ cells expressed pluripotency and Epithelial-
Mesenchymal-Transition (EMT) markers and possessed
differentiation potentials
The expression of pluripotency genes and acquisition of
mesenchymal traits have been shown to indicate a stem cell
phenotype. We demonstrated co-expression of the embryonal
proteins OCT4, NANOG and SOX2 by IF studies on SB from
CD44+ H1299 cells. Semi-quantitative RT-PCR was also
performed on freshly sorted CD44+ and CD442 H1299 cells.
Expression of OCT4, NANOG, SOX2 and the mesenchymal
markers SNAI1, CDH2 and VIM were shown in CD44+ cells but
were lower or undetectable in CD442 cells. Since differential
expression of the standard (s) and variant forms (v3, v5, v6 and v10)
of CD44 has been demonstrated in stem or differentiated cells, we
investigated the pattern of CD44 mRNA splicing by RT-PCR.
Both the standard and variant forms were found in CD44+ but not
CD442 cells, suggesting retention of CD44 mRNA differential
splicing potentials in CD44+ compared to CD442 subpopulation
(Fig. 4A & B).
CD44+ cells were cisplatin-resistant
Freshly sorted CD44+, CD442 and unsorted cells of H1299 and
H1650 were cultured in serum-free RPMI medium and subjected
to 5 mM cisplatin treatment for 24 hr. The histogram in Fig. 4C
represented the average of three individual experiments for both
cell lines. Apoptotic and non-viable cells were measured by
Annexin V and PI staining using flow cytometry, respectively. For
H1299, cisplatin-treatment of unsorted or CD44+ cells resulted in
no significant increase of apoptotic cells compared with their
untreated control, indicating relative cisplatin resistance. CD442
cells showed a significant increase in apoptosis (***p,0.001) after
treatment indicating cisplatin sensitivity. When comparing
amongst the groups, CD442 cells showed significant increases
(### p,0.001) of apoptosis compared to both unsorted and
CD44+ cells, indicating that CD442 cells were the most cisplatin-
sensitive of the 3 groups. Comparable results were also observed
for H1650, indicating relative cisplatin resistance of the unsorted
and CD44+ cells. Furthermore, resistant H1299 cells stably
selected by long term cisplatin treatment showed a higher basal
percentage (96.2%) of CD44+ cells compared to the parental cells
(82%). Likewise, for H1650, basal CD44+ percentage increased
from 61.5% to 92.9%. The results indicated resistance and a
survival advantage of CD44+ cells under chronic cisplatin
treatment (Supplementary Figure S2).
Immunohistochemical analysis of cancer stem cell
markers in NSCLC specimens
To evaluate the in vivo protein expression of CD44 expression,
IHC was performed on arrayed tumor cores of 141 primary lung
carcinomas and reactive or fetal lung tissues. In the control tissues,
cell membrane expression of CD44 was observed in basal cells of
respiratory or metaplastic squamous bronchial epithelium, and
regenerating cuboidal pneumocytes of injured lung. No expression
was observed in terminally differentiated epithelial cells such as
ciliated or non-ciliated columnar cells of bronchial epithelium, or
type I flat pneumocytes lining alveolar spaces. In first trimester
human fetal lung, CD44 was expressed in the epithelium of
primitive airways (Fig. 5A). In lung cancers, expression was present
in alveolar macrophages and small lymphocytes which served as
internal positive controls. Totally, 62/141 (50.4%) cases showed
CD44 expression. SCC was significantly associated with moderate
to strong expression (21/27, 77.8%) compared to AD (41/96,
Table 3. In vivo Serial Transplantation Experiments of CD44+ and CD442 Cells Sorted from H1299 Xenograft Tumor.
Cell type Cell number injected Secondary tumor incidence Latency (days) Tertiary tumor incidence Latency (days)
unsorted 200,000 3/4 28
CD44+ 500 0/4 N/A 0/4 N/A
1,000 0/4 N/A 2/4 14
5,000 2/4 21 3/4 14
10,000 2/4 21
50,000 3/4 14
CD442 1,000 0/4 N/A
5,000 0/4 N/A
50,000 0/4 N/A
100,000 0/4 N/A
N/A: results not available; blank: tests not done or number of cells unavailable.
doi:10.1371/journal.pone.0014062.t003
Figure 3. In vivo tumorigenicity assay of H1299 cells. A. Representative pictures of primary xenograft tumors. Tumor initiation was achieved by
200,000 unsorted cells (3/4 mice). From CD44+ cells, tumors were initiated by 10,000 (1/4 mice), 50,000 (3/4 mice) and 100,000 cells (4/4 mice). No
tumor was formed with 200,000 CD442 cells (0/4 mice). PBS, saline injection control. B. Flow cytometry analysis of disaggregated primary and
secondary xenografts showed similar CD44+ to CD442 subgroup ratios as parental H1299 cells. X-axis: CD44 expression, FITC channel; Y-axis: Dead
cells stained by PI, PE channel. C. Semi-quantitative RT-PCR analysis of primary xenografts showed expression of CD44 standard form (CD44s) and
pluripotency genes (POU5F1, NANOG, SOX2) in CD44+ but not CD442 subgroups. D. IHC analysis of xenografts from sequential generations of
recipient mice showed CD44 expression in cell membrane distribution. Host cells of mouse origin present in the tumor stroma were not stained.
Tumor growth curves of the primary, secondary and tertiary xenograft tumors formed by unsorted and CD44-sorted H1299 cells were plotted by
observing and measuring tumor formation weekly for up to 9 weeks, afterwhich mice were scarified to avoid overgrowth of tumors.
doi:10.1371/journal.pone.0014062.g003
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42.7%) (p = 0.002) (Fig 5B). In SCC showing moderate to well
differentiation, CD44 was expressed much more strongly in the
basal compared to maturing tumor cells (Fig. 5B), consistent with
the expected stem cell niches. When only AD were considered,
CD44 expression showed a weak association with non-smokers
(p = 0.024). For AD, Log Rank test showed that patients with
negative or weak CD44 expression had a significantly worse
overall (p = 0.015) but not progression-free survival. For SCC, no
significant relation of survival with the level of CD44 expression
was observed. No association with other clinicopathological
parameters including patient age, gender, tumor grade, size,
stage, lymph node status, or pathological stage was observed
(Supplementary Table S2). CD133 expression was detected only in
scattered small cells in the stroma of fetal and reactive adult lung
tissues. The basal bronchiolar epithelium, regenerating pneumo-
cytes or tumor cells were negative. CD34 was detected in
endothelium and reactive stromal cells in some tumors but not
cancer cells. To ensure that the absence of staining was not due to
regional variation of cellular distribution, the results were validated
by repeating IHC analysis on full sections of cancer in selective
cases.
Discussion
The hypothesis that cancers are maintained by a subpopulation
of stem or progenitor-like cells while non-stem/progenitor cells
have a finite life span raises the possibility that targeting specific
components of the regulatory pathways of cancer stem cell
maintenance could provide a means of cancer control. As a
preliminary step to investigate whether this hypothesis is
applicable to lung carcinomas, it is necessary to identify and
isolate cancer initiating cells using suitable markers. While the
optimal approach for this purpose is still being explored, flow
cytometric analysis and sorting of marker-positive cells is currently
Figure 4. Functional characterization of CD44-selected H1299 cells. A. Immunofluorescence characterization of SB from CD44+
subpopulation, showing co-expression of OCT4, NANOG and SOX2. DAPI, control; Green, OCT4-FITC; Red, SOX2-Texas Red; Blue, pseudocolor of
NANOG by PE-conjugated antibody. B. Semi-quantitative RT-PCR analysis showed pluripotency genes, SNAI1, CDH2, VIM, CD44s and CD44 v3,5,6,10
expression in CD44+ cells. CD442 H1299 cells lack these expression except for CDH2 and VIM. C. CD44+ cells were more resistant to the apoptotic
effects of 5 mM cisplatin compared to CD442 in H1299 and H1650 cells after 24 hr incubation. Histograms represented average of three individual
experiments of unsorted, CD44+ and CD442 cells before and after cisplatin treatment.
doi:10.1371/journal.pone.0014062.g004
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the most widely applied method [24]. Amongst the surface
markers studied, we have shown that CD44+ cells are enriched for
tumor propagating capacity and CD44 is a potential CSC marker
of NSCLC cell lines. In a recent study on metastatic lung cancers
in malignant pleural effusion, CD44 was also reported as a possible
stem cell marker but the characterization of stem cell-like
properties was based on in vitro molecular analysis and cellular
expansion only [16]. In our study, in vitro and in vivo tumorigenecity
of CD44+ cells was shown. Furthermore, our xenograft experi-
ments showed a progressive enhancement of transplantation
efficiency in successive tumor generations with shortening of
latency period and decreased minimal cellular dose of engraft-
ment. An increasing tumor formation capacity was also reported
by Du et al. who investigated CD44+ subpopulations of colon
cancer cells [25]. Breast epithelial cells induced to undergo EMT
were shown to acquire stem cell-like and tumorigenic characters
[26]. In our study, CD44+ cells were also associated with
expression of markers implicating EMT such as SNAI1, CDH2
and VIM. Only CD44+ cells expressed the pluripotency genes
POU5F1, NANOG and SOX2 [10,27,28,29], while these markers
were lost in CD442 cells, suggesting that EMT may be involved in
maintaining stemness. Further investigations are needed to
elucidate the underlying mechanism and interaction between
these transcription complex proteins and CD44 expression.
Figure 5. IHC analysis of human lung tissues. A. CD44 expression in pseudoglandular stage of embryonic lung (left) and regenerating
pneumocytes of lung with diffuse alveolar injury (right). Inset shows CD44+ basal cells in normal bronchial epithelium. B. Representative cases of
adenocarcinomas (AD) showing moderate (left) and strong (right) CD44 expression in cell membrane distribution. In some cases of squamous cell
carcinomas (SCC), CD44 expression was particularly prominent in tumor cells at the periphery (arrow) than central regions (asterisks) of tumor islands
which are generally regarded as stem cell sites. Scattered small lymphocytes and marcophages also showed CD44 expression in the tumor stroma. C.
Kaplain Meier survival analysis of patients with AD (upper panel) and SCC (lower panel) stratified according to CD44+ (tumors with moderate/strong
expression) or CD442 (absent/weak, focal staining). PFS, progression-free survival in months; OS, ovrall survival in months.
doi:10.1371/journal.pone.0014062.g005
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In cultured H1299 and H1650 cells, CD44+ cells demonstrated
a lower basal apoptotic level and relative resistance to cisplatin
treatment compared to CD442 cells. This indicates their resilience
against chemotoxicity and capacity to maintain tissue homeostasis,
features believed to be associated with tissue stem cell phenotype.
On the other hand, when CD44+ cells were transplanted from the
in vitro to in vivo environment triggering marked cell loss through
apoptosis, a 100 fold reduction of tumor cells was able to initiate
tumors at a faster rate in sequential mice generations, demon-
strating the robustness of the stem cell-like subpopulation
contained in the selected cells. This could also indicate that only
a portion of the CD44+ cells were required for tumor initiation,
and that the increasing tumorigenecity of CD44+ cells was due to
in vivo enrichment of CSC. Further marker studies and refined
selection criteria are necessary for more specific in vitro CSC
isolation.
CD133 is the most commonly reported marker and has been
used to isolate CSC from fresh lung cancers [13,15] but in our
study, most cancer cell lines showed no significant CD133
expression by either semi-quantitative RT-PCR (data not shown),
IHC, immunoblotting (Fig. 2A) or flow cytometry analysis
(Table 1). Using the same anti-CD133 antibody, Chen et al.
observed only 0.7% CD133 expression in H1299, while no
expression was found in our study [11]. Amongst our studied cell
lines, only HCC1833 showed SB formation on CD133-selection
but in vivo tumorigenecity could not be demonstrated. Use of other
mice species which are immunologically more tolerant towards
xenografts might reveal different results. No data on HCC1833
are available in the literature for comparison. Stuelten et al also
found infrequent CD133 expression in the NCI60 cancer cell
panel [30]. CD44 expression was observed but in two cell lines,
their findings differed from ours. We observed 0% and 95.9% of
CD44 in A549 and H23, but 84.41% and 30.95%, respectively,
were detected by the investigators [30]. We cannot explain the
differences but data of other cancers have also reported discrepant
observations. For example, one study reported 38–72% of
CD133+ cells in the ovarian cancer cell line SKOV3 while the
percentage found by Stuelten et al was only 0.78%. Different
marker percentages have also been found in colon and liver cancer
cells [30,31,32]. The inconsistency of CSC marker profile
expression amongst different studies could be related to individual
cancer variation, but they could also be due to different potency
states, compositional or functional characteristics of the cancer
stem or progenitor populations. In the absence of a specific
marker, the true percentage of CSC in a tumor, particularly that
in long-established cancer cell lines, is controversial [24]. The
variation in environmental and selective pressures experienced by
cancer cells in vitro and in vivo might trigger or suppress different
pathways of the molecular networks that regulate CSC functions,
and it is not clear whether the CSC marker profile could vary with
circumstances. While we have demonstrated that CD442 cells are
incapable of tumor perpetuation, more refined methods for CSC
selection and characterization are clearly needed. It would be
worthwhile to explore whether CD44 could be combined with
other potential CSC markers such as ALDH, CXCR4, ABCG2,
side population marker, ESA, etc., for improving the efficiency
and specificity of CSC selection [13,21,22,33].
CD44 is a membrane bound glycoprotein which mediates a
complex range of functions. Recent studies have provided support
for its role as a CSC marker. For example, the clonal expansion
and xenograft initiation capacity of CD44+-selected colorectal
cancer CSC could be inhibited by CD44 knockdown [25].
Homozygous CD44 deletion affected intestinal crypt cell survival
and attenuated tumorigenecity without affecting proliferation in a
primary mouse colon carcinoma model [34]. Mechanistically,
invasive and metastatic growth can be mediated through the
interaction of cell surface CD44 with extracellular matrix
components such as hyaluronan with subsequent changes induced
in the cytoskeletal machinery of cancer cells [35]. CD44 expressed
on the surface of colon cancer cells has been shown to facilitate
binding to endothelial P- or L-selectin and increase tumor access
to haematogenous spread [36]. CD44 is also networked to many
signaling cascades that mediate tumor-enhancing functions. It acts
as a co-receptor with neighboring EGFR or other ErbB family
receptors tyrosine kinases [37], and can activate cell proliferation
pathways indirectly through ligand presentation such as the scatter
factor to its receptor c-MET [38]. Tumor cell survival could also
be enhanced through activation of anti-apoptotic pathways such as
the PI3K/AKT cascade [39,40] and Bcl2 and Bcl-xL transcription
factors [41]. A report on small cell lung cancers showed that
activation of CD44-MAPK-PI3K signaling led to increased
expression of uPA/uPAR and MDR1, resulting in enhanced
invasive and multi-drug resistant cancer phenotypes [42]. It has
been suggested that variant forms of CD44, especially CD44v6
which is transiently expressed during embryonic lung develop-
ment, mediates tumor cell migration and invasion and can suffice
for a CSC marker [43]. Notably, in our CD44+-derived SB and
xenografts, mRNA of both the standard and variant forms of
CD44 were expressed.
Immunohistochemical analysis using a monoclonal antibody
against the standard form of CD44 showed that in non-cancer
lung, CD44 is not expressed in terminally differentiated lung
epithelium but is upregulated in sites generally regarded as reserve
or stem cell niches and in regenerating alveolar lining cells of
injured lungs. Our data as well as those from several studies have
shown a significantly more frequent CD44 expression in squamous
compared with adenocarcinoma histology. Interestingly, meta-
plastic squamous epithelium of bronchi displays increased
hyaluronan and CD44 expression in the proliferating basal layers,
while in premalignant dysplasia, the entire thickness shows
aberrant hyaluronan-CD44 expression, indicating that squamous
malignant transformation is closely associated with CD44
expression [44]. For AD, the picture is less clear, perhaps related
to their heterogeneous histogenetic origin. In the literature,
associations of immunohistochemical CD44 expression with either
a better or a worse patient outcome have been reported [43,45]. In
our study, we have observed an association of CD44 expression
with longer survival in AD (p= 0.015) (Fig. 5C). This observation
is contrary to conventional expectation that tumors enriched for
stem cell properties would be biologically more aggressive. On the
other hand, in vitro models have shown that lower hyaluronan
levels could promote angiogenesis and support tumor progression
[39]. Given that CD44 is a receptor of hyaluronan, it would be
worth investigating whether CD44 expression would also be
reduced and associated with tumor progression and a worse
patient outcome. In tumors showing extensive CD44 expression, it
is possible that not all tumor cells are responsible for tumor
initiation. Whether CD44 expression is regulated by non-stem cell
related pathways in clinical tumors need to be examined. A better
understanding of the role of CD44 and its interaction with
hyaluronan and other binding partners in tumor initiation and
progression would be required to clarify its relation with patient
outcome.
In summary, this study has provided evidence that amongst
reported CSC markers such as CD133, ALDH, CXCR4, ABCG2,
ESA and side population staining, CD44 could be a potentially
useful marker for lung cancers. Further experiments using more
refined selection criteria such as a combination of two or multiple
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markers would be useful to specifically identify and purify CSC.
Testing on resected tumor samples or pleural effusion fluid would
help to clarify its applicability in clinical settings. Further
investigations of the roles and mechanistic pathways of CD44 in
tumor initiation and progression are required to validate its role in
CSC maintenance and regulation, and provide further insight on
its usefulness as a specific therapeutic target.
Materials and Methods
Cell lines and cultures
Ten human non-small cell lung cancer cell lines were obtained
from ATCC or kindly provided by Dr. JD Minna. HKULC2 and
HKULC4 cell lines were raised from Hong Kong patients as
reported previously [46]. PLC8024 was a liver cancer cell line
kindly provided by Dr. KW Chan [4]. All cells were maintained in
RPMI medium with 10% fetal bovine serum supplement. Stable
cisplatin-resistant H1299-CR and H1650-CR cell lines were
generated by culturing the parental H1299 and H1650 cell lines,
respectively, with increasing dose of cisplatin for 3 months. Single
resistant clones were expanded in RPMI full medium and were
retested to show cisplatin resistance.
Animals
Ncr-nu/nu-nude mice were maintained under pathogen-free
conditions. All animal experiments were performed according to
National Institutes of Health guidelines and approved by the
Institutional Animal Care and Use Committee at Nevada Cancer
Institute (Animal protocol number 05-001).
RNA isolation, cDNA synthesis and semi-quantitative
reverse-transcription polymerase chain reaction
Total RNA was extracted using TRIZOL reagents (Invitrogen).
One mg of the extracted RNA was used for cDNA synthesis using
first-strand cDNA kit according to the manufacturer’s instructions
(Invitrogen) and subjected to semi-quantitative reverse-transcrip-
tion polymerase chain reaction (RT-PCR). PCR amplifications for
POU5F1 (OCT4), NANOG, SOX2, SNAI1, CDH2, VIM, PROM1
(CD133), CD44s, CD44v3, CD44v5, CD44v6, CD44v10 and
GAPDH were performed for 40 cycles using primers and
conditions listed (Supplementary Table S1).
Flow cytometry analysis and fluorescence-activated cell
sorting
Expression of cancer stem cell markers was evaluated by flow
cytometry. Dead cells, cell debris and doublets were first gated out
using either PI or Live Dead dye (Invitrogen), or based on cell size
and complexity. Single color compensation controls were
performed in each experiment for non-specific spectral signals
emitted by the fluorochromes [24,47]. Cells were labeled with
mouse origin direct fluorochrome-conjugated antibodies from BD
Bioscience. The antibodies consistsed of anti-CD34-PE (Cat.
No. 560941), anti-CD44-fluorescein isothiocyanate (FITC) specif-
ic for CD44 standard form (Cat. No. 555478), anti-OCT4-PE
(Cat. No. 560186), anti-BMI1-FITC (Cat No. 612666)] and
Miltenyi Biotech [anti-CD133-PE (Cat. No. 130-080-901)] at the
concentration recommended by the manufacturers. For intracel-
lular staining of OCT4 and BMI1, cells were prefixed and
permeablized with Fix & Perm cell permeabilization Kit
(Invitrogen) before adding the antibodies. Corresponding iso-
type-matched mouse immunoglobins were used as negative
controls (BD Bioscience). Consistent labeling protocols were used
in each experiment. At least 10,000 cells were acquired for each
analysis. For cell sorting, labeling of cell surface markers was
performed under sterilized conditions and cells were sorted by BD
FACSVantage Cell sorter (BD Bioscience). The top 25% most
brightly stained, and the lowest 20% most dimly-stained cells were
selected as the positive and negative populations, respectively.
Sorting purity of over 90% was ensured for further in vitro and in
vivo experiments. All data were analyzed by the Flowjo software,
version 5.7.2 (Tree star).
Immunoblot
Cells were harvested and washed with 16PBS and lysed on ice
with RIPA Lysis buffer [10mM Tris, 150mM NaCl, 1mM
ethylenediaminetetraacetic acid, 1% Triton X-100, 0.5% NP40,
pH 7.4, freshly added 0.2mM PMSF in isopropanol, 1:50
Phosphatase Inhibitor Cocktail 2 (Sigma), 1:50 Protease Inhibitor
Cocktail (Sigma)] for 1 hr. The cell lysate was then centrifuged at
13k rpm for 20 min at 4uC to remove cell debris. The protein
amount in the lysate was quantified with the Dc Protein Assay
(Bio-Rad). For each lysate, 30mg protein was loaded on SDS-
PAGE and then transferred onto PVDF membranes (Amersham).
The membranes were blocked by incubation with shaking in 1%
BSA blocking buffer at room temperature for 1 hr. Primary
antibodies of CD133 (Miltenyl Biotech), CD44 and ACTIN (Cell
signaling) were diluted at 1:1000 in TBS/Tween 20 with 5% BSA.
Secondary antibody was diluted in 1% BSA blocking buffer.
Target proteins on the membrane were visualized on X-ray films
by using the ECL Plus Western Blotting Detection Reagents
(Amersham, Buckinghamshire, UK). Results were obtained from
at least 3 independent experiments and representative results were
shown.
Spheroid culture and in vitro serial transplantation
Freshly isolated CD44+ and CD442 cells were cultured in low
adherent 35mm dishes (Costar) under serum-free condition and
supplemented with 20 mg/ml of insulin, 20 mg/ml EGF and
10 mg/ml of bFGF (Invitrogen) for 21 days according to published
protocols [14]. In brief, SB were harvested every 3 days,
centrifuged at 1200rpm for 5 mins and washed once with 16
PBS. SB were then re-cultured with fresh serum-free medium and
supplements in low adherent dishes. Floating spheroid-like bodies
(SB) were photographed by random field selection. Harvested SB
were mechanically dissociated and seeded again in low adherent
culture plates supplemented with growth factors for in vitro serial
SB subculture. At least 3 passages were performed for each cell
line. SB were also collected for immunofluorescence or RNA
extraction and subsequent expression analyses. Data were
collected from at least three independently performed experi-
ments.
Immunofluorescence staining for surface stem cell and
‘stemness’ gene markers
SB were stained with standard immunofluorescence (IF)
protocol. Briefly, SB were put into 96 wells floating plate, and
were stained with direct anti-CD44-FITC conjugated antibodies
(BD Bioscience), or anti-OCT4, anti-NANOG and anti-SOX2
antibodies (Santa Cruz Biotechnology) at 4uC overnight. For
intracellular staining of OCT4, NANOG and SOX2, cells were
prefixed and permeablized with Fix & Perm cell permeabilization
Kit (Invitrogen) according to manufacturer instruction before
adding the antibodies. SB were then washed with 16 PBS for
three times. Appropriate secondary antibodies (anti-rabbit-PE,
anti-mouse-FITC or anti-goat-Texas Red) were added and images
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were visualized with a fluorescence microscope and imaged with a
CCD camera.
Apoptosis assay
For apoptosis assay, 5000 freshly isolated CD44+, CD442 and
unsorted cells were treated with vehicle or Cisplatin (5 mM) for
24 hr, cells were then cells were stained with Annexin V-FITC
and PI according to the manufacturer’s instruction (BD Biosci-
ence). Cells were then washed and resuspended with 16 binding
buffer. The numbers of Annexin V and PI-positive cells were
counted by flow cytometer.
Anchorage-independent growth assay
Unsorted, CD44+/2-sorted cells were suspended in soft agar
and growth medium in 6-well plates at density of 5000 cells per
well. After 3–4 weeks, colonies were counted under the microscope
in 10 fields per well and photographed.
In vivo tumorigenicity experiment and serial
transplantation
For mouse xenografts, a range of numbers of freshly isolated
unsorted, CD44+/2 and CD133+/2 from all seven cell lines were
mixed with growth factors and matrigel, and injected (using 27-
gauge needle) subcutaneously into the back of four weeks old nude
mice (nu/nu). Mice were monitored for subcutaneous tumors
weekly for up to 9 weeks. Tumor volume (TV) was calculated
according to the formula: TV (cm3) = d26D/2, where d and D
were the shortest and the longest diameters, respectively. Tumor
growth curves were plotted. When tumor diameters reached at
least 1cm in size, mice were scarified and tumor tissues were
collected for morphological assessement. All tumor tissues were
harvested. Parts of the tumors were processed for morphological
and immunohistochemical analysis. Remaining tissues were
subjected to further flow cytometry marker analysis and in vivo
serial transplant.
To test for in vivo serial transplantation, primary xenografts from
H1299 CD44+ cells were digested with collagenase type II (2 mg/
ml) under constant rotation for 2 hr at 37uC. Cells were washed,
collected and passed through a 75 mm strainer (BD Bioscience).
Cells were stained with anit-CD44-FITC antibodies, reanalyzed
for CD44+ percentage and sorted. The unsorted, CD44+ and
CD442 cells were injected into secondary recipient nude mice and
monitored for tumor formation. Subsequently, secondary tumors
were sorted and transplanted into tertiary recipient mice by the
same method. The required numbers of cells and latency period
for tumor formation were recorded.
CD44 and CD133 expression analysis in clinical tumors,
xenograft tumors and cell blocks by IHC
Resected tumors of 141 primary NSCLC from untreated
Chinese patients were studied for CD44 expression. Cores of
tissues of 0.6mm diameter in 3 to 4 replicates were arrayed on
paraffin blocks, using normal lung, liver and gastrointestinal tract
tissues as control, and a constant sample of lung carcinoma for
normalization across different tissue array blocks. Tumor typing,
staging criteria and definitions of smoking history were as
previously described [48]. Deparaffinized tissue sections and cell
blocks were blocked by background sniper (BiocareMedical) and
peroxidase (BiocareMedical). Sections were labeled with primary
antibodies against CD34 (clone QBEnd/10; BiocareMedical) and
CD44 standard form (clone 156-3C11; BiocareMedical) and
CD133 (clone CD133/1; Mitenyl Biotech) at 1:200 dilution for
30 mins at room temperature. Subsequent steps of polymer-based
detection system were performed according to the manufacturer’s
suggestions (BiocareMedical). For xenograft tumor, the same
primary antibodies were used but sections were treated with
biotin-blocking (DAKO) and mouse Ig blocking reagents. The
Mouse on Mouse Immunodetection kit (Vector Laboratories)
comprising IgG biotinylated anti-mouse secondary antibodies and
ABC reagents (Vector Laboratories) were used and color detection
was performed by DAB substrates (BiocareMedical). For control,
the primary antibody was replaced with universal negative control
serum (BiocareMedical). Images of stained sections were acquired
by an automated scanner and the protein expression level was
semi-quantitatively measured by an image analysis system
(Aperio). Tumor cells not showing any degree of staining were
counted as negative. Those showing only faint staining were
considered weak; cells showing membrane staining similar in
intensity to basal cells of bronchiolar epithelium were considered
moderate, and those with more intense staining were considered as
strong. Tumors showing any proportion of cells with moderate or
strong staining were considered as positive. Tumors showing none
or weak staining were grouped and compared to those showing
positive expression.
Statistical analysis
Differences between experimental groups were analyzed by
One way ANOVA (Bonferroni multiple group analysis test) for SB
formation, clonogenicity and cisplatin sensitivity study using
GraphPad PRISM software, version 3.0 (GraphPad Prism).
Statistical analysis of IHC results and comparison with clinico-
pathological data were performed by the x2 test, Fisher exact test
or Mann-Whitney U test where appropriate, and survival data by
Kaplan Meier analysis using SPSS version 16.0 (SPSS Inc.). The
two-sided significance level was set at p,0.05.
Supporting Information
Figure S1 Percentage of Spheroid Bodies (SB) Formation of
Unsorted and Sorted Cells in Seven NSCLC Cell Lines.
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TIF)
Figure S2 Representative Flow Cytometry Diagrams of Basal
CD44 Percentage Analysis of Parental and Cisplatin-resistant
H1299 and H1650 Cell Lines.
Found at: doi:10.1371/journal.pone.0014062.s002 (8.09 MB TIF)
Table S1 PCR Conditions and Primer Sequences.
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Table S2 Immunohistochemical CD44 Expression and Clinico-
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